Dow Up0.07% Nasdaq Up0.61%

Oncothyreon Inc (ONTY)

1.86 0.17(10.06%) Nov 26, 4:00PM EST
ProfileGet Profile for:
Oncothyreon Inc
2601 Fourth Avenue
Suite 500
Seattle, WA 98121
United States - Map
Phone: 206-801-2100
Fax: 206-801-2101

Index Membership:N/A
Full Time Employees:43

Business Summary 

Oncothyreon Inc, a clinical-stage biopharmaceutical company, develops therapeutic products for the treatment of cancer. Its product candidate includes Tecemotide, a vaccine for the treatment of non-small cell lung cancer. The company is also developing ONT-10, a cancer vaccine, which is in Phase I clinical trial for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate cancers, as well as various lung cancer; ONT-380, a small-molecule HER2 inhibitor that is in Phase Ib trial for the treatment of metastatic breast cancer, including patients with brain metastases; and PX-866, which has completed two Phase II trials for the treatment of various cancers. In addition, it develops PET lipid-A, a proprietary synthetic lipid-A analog. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Oncothyreon Inc

Corporate Governance 
Oncothyreon Inc’s ISS Governance QuickScore as of Nov 1, 2014 is 5. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 3.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Robert L. Kirkman M.D., 65
Chief Exec. Officer, Pres and Director
Ms. Julia M. Eastland , 49
Chief Financial Officer, Principal Accounting Officer and VP of Corp. Devel.
Mr. Gary Christianson PE, 59
Chief Operating Officer
Dr. Scott Robert Peterson Ph.D., 52
Chief Scientific Officer
Dr. Diana F. Hausman M.D., 51
Chief Medical Officer
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders